GlassScriptPhysician profile
Abdul B Usmani
NPI 1629235700
$3,840.13
in general payments reported to CMS, 2019-2025
28 companies · $929 in 2025
The $929 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $308 · 2021: $354 · 2022: $628 · 2023: $703 · 2024: $781 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $538.97 | 2021-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $529.94 | 2020-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $488.52 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $284.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $236.31 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $207.82 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $182.21 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $177.66 | 2023-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $166.73 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $139.38 | 2022-2025 | Lupkynis |
| Scpharmaceuticals INC. | $114.46 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $109.03 | 2022-2024 | Tarpeyo |
| Rockwell Medical, INC. | $90.40 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.25 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $72.44 | 2023-2025 | Purified Cortrophin Gel |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $68.30 | 2022-2025 | Veltassa |
| Ardelyx, INC. | $51.32 | 2024 | Ibsrela |
| Sumitomo Pharma America, INC. | $48.14 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $42.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $39.99 | 2021-2024 | Ultomiris |
| Akebia Therapeutics INC | $28.86 | 2025 | Vafseo |
| Daiichi Sankyo INC. | $27.84 | 2021 | |
| Avion Pharmaceuticals | $27.66 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.48 | 2021 | |
| Ascendis Pharma Endocrinology INC | $17.95 | 2025 | Yorvipath |
| Arbor Pharmaceuticals, INC. | $16.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.47 | 2019 | |
| Biomerieux INC | $9.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Usmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.